Dr. Moshe Ephrat, MD

Dr. Ephrat practices at ENT and Allergy Associates in New Hyde Park, New York.

Dr. Ephrat's NPI, 1134109879, was assigned on January 19, 2006. Dr. Ephrat graduated from Albert Einstein College of Medicine in 1993. Dr. Ephrat holds New York license 199565.

Dr. Ephrat's primary practice is ENT and Allergy Associates, at 6 Ohio Dr, New Hyde Park, NY 11042 in Nassau County. The practice phone is (914) 333-5800.

Dr. Ephrat's primary practice is ENT and Allergy Associates in New Hyde Park, New York. Dr. Ephrat is also affiliated with Long Island Jewish Medical Center. The medical group on file is ENT and Allergy Associates. Dmand AI also links Dr. Ephrat to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ephrat practices, 4 sites in all. Vendor and product names are available with a free account.

Facial plastic surgery is Dr. Ephrat's primary specialty in the NPI Registry, under taxonomy code 207YS0123X. Dr. Ephrat is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Ephrat's licenses on file in 3 states: New York, New Jersey and Louisiana.

Dmand AI lists acute sinusitis, chronic nasal allergies, chronic sinusitis, ear eustachian tube disorders, ear infection, endoscopic sinus surgery, hearing loss and impairment and swimmer's ear among the conditions Dr. Ephrat treats.

CMS data shows 3,085 Medicare services from Dr. Ephrat across 13 procedure codes in 2024, for 1,110 Medicare patients. Medicare paid $317,297 for them. Every service was in an office.

CMS counts 1,110 Medicare patients who saw Dr. Ephrat in 2024. The largest group is 65 to 74, with 476 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ephrat's median patient age at 58, with 55% women.

In 2024, Dr. Ephrat wrote 1,375 Medicare Part D claims for 535 patients. 95% of them were for generic drugs. CMS names the drug for 1,301 of them, across 20 drugs with 11 or more claims each, at $57,806 in total drug cost. In 2023, CMS named 1,136 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Ephrat for performance year 2024, reported as part of a group. Dr. Ephrat accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Ephrat, published from 2019 to 2022. 2020 was the busiest year, with 2. Dr. Ephrat's most frequent co-authors are Mark S. Driver, MD and Ofer Jacobowitz, MD, PhD.

Dmand AI links Dr. Ephrat to 3 clinical trials. Conditions studied include Pathological Conditions, Signs and Symptoms, Nasal Obstruction and Airway Obstruction. Lyra Therapeutics sponsors the most, 2.

CMS Open Payments shows 689 general payments to Dr. Ephrat from 45 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $92,492.

Dmand AI lists 3 awards for Dr. Ephrat, most recently CMS Stage 1 EHR in 2013.

Dr. Ephrat graduated from Albert Einstein College of Medicine in 1993. Dr. Ephrat is a member of NHS, ACS and AMA.

Dr. Ephrat is in network with 12 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.